Chimeric Therapeutics Ltd Launches Strategic Review to Unlock Cell Therapy Value
Chimeric Therapeutics launches adviser-led strategic review to unlock value
Chimeric Therapeutics (ASX: CHM) has appointed Hawkesbury Partners Pty Limited as its Independent Financial Adviser to undertake a review of strategic options, with the stated objective of “maximising shareholder value.”
The move comes as the Board signals it believes the value embedded in its cell therapy portfolio is not currently reflected in the Company’s market capitalisation, following over A$80 million invested across its clinical programmes and supporting infrastructure.
Importantly, the Company has been explicit that there is no certainty any transaction will result from this process. The review is a structured evaluation of options, not a confirmed deal.
When big ASX news breaks, our subscribers know first
Why the Board is acting now
At the centre of the review is a perceived value gap. Chimeric has invested over A$80 million in building its clinical programmes alongside the manufacturing, quality and regulatory infrastructure that underpins them. The Board has determined that this embedded value is not currently captured in the Company’s market capitalisation.
To address that disconnect, the Board has tasked Hawkesbury Partners with identifying and evaluating opportunities to monetise and realise value for shareholders. According to the announcement, the mandate may include:
-
Strategic partnerships and funding
-
Licensing arrangements
-
Co-development agreements
-
Mergers
-
Asset sale transactions
-
Alternative capital structures
These represent options under evaluation rather than planned transactions. The Board has reiterated that there is no certainty any transaction will result from the process, and the breadth of the mandate reflects a structured assessment of all available paths rather than a commitment to any single one.
Who is Hawkesbury Partners
Hawkesbury Partners is a corporate and capital markets advisory firm providing capital raising, mergers and acquisitions (M&A) and strategic advisory services, with deep expertise supporting life sciences companies.
The firm holds Australian Financial Services Licence 432 322 and has confirmed to the Board that it is independent and conflict free for the purposes of this engagement. For investors, the appointment of an independent, conflict-free adviser with life sciences experience lends procedural credibility to the review.
Understanding a strategic review
An adviser-led strategic review is a structured process in which a company’s board engages an independent financial adviser to assess the full range of options available to realise value from its assets. These options can span partnerships and licensing through to mergers or outright asset sales.
A board typically initiates such a review when it believes the market is not adequately valuing the business or its underlying assets. Rather than committing to one path, the process is designed to evaluate all alternatives side by side.
For investors, the significance is twofold. It signals that the Board is proactively addressing a perceived value gap. At the same time, both the outcome and the timing remain uncertain, and a review does not guarantee any particular result.
What’s inside Chimeric’s portfolio
The review is built around a diversified clinical-stage portfolio. Chimeric describes itself as an Australian cell therapy company with 4 clinical stage programs, spanning first-in-class autologous CAR T cell therapies and best-in-class allogeneic NK cell therapies across multiple oncology disease areas.
The two lead programmes are summarised below.
| Programme | Type | Indication | Status |
|---|---|---|---|
| CHM CDH17 | First-in-class, 3rd generation CDH17 CAR T | Gastrointestinal & neuroendocrine tumours | Phase 1/2 (initiated 2024) |
| CHM CORE-NK | Potentially best-in-class NK cell platform | Blood cancers & solid tumours | Phase 1A complete; two Phase 1B trials initiated |
CHM CDH17 was invented at the University of Pennsylvania, while CHM CORE-NK is described as a clinically validated platform from which Chimeric has initiated development of next generation NK and CAR NK assets.
The CDH17 programme has accumulated meaningful clinical evidence to support that case, with an 82% disease control rate across 11 evaluable patients reported at ASCO in June 2026, alongside 100% manufacturing success across 15 production runs and CAR T cell persistence observed at up to 15 months post-infusion.
The next major ASX story will hit our subscribers first
What happens next
The review is now underway. The Company has stated it will update the market on material developments as they arise, consistent with its continuous disclosure obligations. The focus at this stage is on process rather than any predetermined outcome.
The Board has again emphasised that there is no certainty any transaction will result from the review.
The Board’s Stated Objective
The Board has framed the review around a single goal: maximising shareholder value, by identifying and evaluating opportunities to realise the value of Chimeric and its assets for the benefit of shareholders.
For investors, the takeaway is clear. The Board is actively seeking to surface value in a portfolio it considers undervalued relative to the more than A$80 million invested to date, while being transparent that no deal is guaranteed and that both outcome and timing remain uncertain.
Don’t Miss the Next Healthcare Breakout
Big News Blast delivers FREE breaking ASX healthcare and biotech news to your inbox within minutes of release, complete with in-depth analysis. Join 20,000+ subscribers already staying ahead of the market. Click the “Free Alerts” button at StockWire X to get the next market-moving announcement the moment it drops.